6533b7ddfe1ef96bd1273d1b
RESEARCH PRODUCT
Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Henning Schulze-bergkamenElisabeth SchnoyDirk WaldschmidtStefan KubickaPatrick MichlChristoph KahlVolker EndrisHanno RiessArndt VogelKirsten MerxMichael GeisslerAndreas BlockStefan KasperMarkus MoehlerWilko WeichertJan KuhlmannMichael BitzerJens T. Sivekesubject
OncologyCancer Researchmedicine.medical_specialtyBiliary tract cancerbusiness.industryColorectal cancerGemcitabine/cisplatinmedicine.disease_causemedicine.diseaseOncologyInternal medicineMedicinePanitumumabKRASbusinessmedicine.drugEGFR inhibitorsdescription
4082 Background: Biliary tract cancer encompasses a group of genetically heterogeneous tumors. Panitumumab is a human EGFR inhibitor and has shown anti-tumor activity in RAS WT colorectal cancer. M...
year | journal | country | edition | language |
---|---|---|---|---|
2015-05-20 | Journal of Clinical Oncology |